miR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR

HCC is a common malignancy worldwide and surgery or reginal treatments are deemed insufficient for advanced-stage disease. Sorafenib is an inhibitor of many kinases and was shown to benefit advanced HCC patients. However, resistance emerges soon after initial treatment, limiting the clinical benefit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Lin, Lin, Zhongjie, Wan, Zhe, Xia, Shunjie, Jiang, Shi, Cen, Dong, Cai, Liuxin, Xu, Junjie, Cai, Xiujun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170966/
https://www.ncbi.nlm.nih.gov/pubmed/32313144
http://dx.doi.org/10.1038/s41419-020-2413-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170966/
https://www.ncbi.nlm.nih.gov/pubmed/32313144
http://dx.doi.org/10.1038/s41419-020-2413-4

Ejemplares similares